drugs.com monograph trastuzumab pregnancy category X legal status routes of administration Intravenous ... Image trastuzumab.gif for rationale Trastuzumab International Nonproprietary Name INN trade name Herceptin ... Hudis 2007 cite journal first CA last Hudis title Trastuzumab mechanism of action and use in clinical ... Antibodies are molecules from the immune system that bind selectively to different proteins. Trastuzumab ... the survival of people with cancer. However, cancers usually develop resistance to trastuzumab. The original studies of trastuzumab showed that it improved overall survival in late stage metastatic ... trastuzumab is effective in earlier stage cancer. ref 129 Herceptin and early breast cancer a moment for caution Editorial . Lancet 2005 366 1673. ref Trastuzumab is also controversial because of its cost, as much as 100,000 per year, ref Cite web url http healthlifeandstuff.com 2009 12 herceptin or trastuzumab efficacy side effects title Herceptin or Trastuzumab Efficacy, Side Effects publisher Health ... systems in Canada, England and elsewhere have refused to pay for trastuzumab for certain patients, some companies have since accepted trastuzumab treatment as a covered preventative treatment. ref ... id 39 year 2006 title At last, Axa pays for Herceptin ref Trastuzumab was originally developed in mice ... into a clone of identical cells, it is called a monoclonal antibody. Trastuzumab is also being studied ... AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. title Trastuzumab treatment in patients with advanced ... by Akt. Trastuzumab is a Humanized antibody humanized monoclonal antibody that binds ... segment of the HER2 neu receptor. Cells treated with trastuzumab undergo arrest during the G1 phase of the cell cycle so there is reduced proliferation. It has been suggested that trastuzumab ... to enter the nucleus and inhibit cdk2 activity, causing cell cycle arrest. ref name Kute Also, trastuzumab .... Trastuzumab has been shown to inhibit HER2 neu ectodomain cleavage in breast cancer cells. ref name ... more details
S sub n sub molecular weight 148.5 kDa smiles Trastuzumab emtansine International Nonproprietary Name INN , ref cite journal pmid 20521224 title Trastuzumab emtansine, an antibody drug conjugate for the treatment of HER2 metastatic breast cancer ref ref http www.ama assn.org resources doc usan trastuzumab emtansine.pdf STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL TRASTUZUMAB EMTANSINE ref also called trastuzumab DM1 or trastuzumab MCC DM1 , abbreviated T DM1 is an antibody drug conjugate consisting of the antibody trastuzumab Herceptin linked to the cytotoxin mertansine DM1 ... trastuzumab MCC DM1 antibody drug conjugate ref ref cite news url http www.news medical.net news 20100827 FDA denies accelerated approval of Genentechs trastuzumab DM1 28T DM1 29 BLA for metastatic breast cancer.aspx title FDA denies accelerated approval of Genentech s trastuzumab DM1 T DM1 BLA for metastatic ... the MARIANNE study will compare docetaxel trastuzumab vs T DM1 vs T DM1 plus pertuzumab the TH3RESA ... Monoclonal antibodies for tumors monoclonal antibody stub it Trastuzumab emtansine ... more details
Orphan date May 2011 refimprove date April 2011 A predictive marker is a particular protein or gene that indicates sensitivity or resistance to a specific therapy . The use of predictive markers is becoming increasingly relevant in cancer therapy as it allows for better identification of patients who will respond positively to the therapy. In the clinical setting, predictive markers are limited to use in breast cancer . ref cite journal last Duffy first Michael title Predictive Markers in Breast and Other Cancers A Review journal Clinical Chemistry year 2005 volume 51 pages 494 503 url http www.clinchem.org cgi content full 51 3 494 accessdate 2011 04 04 issue 3 pmid 15637130 month March ref Expression of estrogen and progesterone receptor s can determine the benefits of hormone therapy , whilst the benefit of treating breast cancer patients with Trastuzumab herceptin Trastuzumab is determined by the expression of HER2. There are many advantages to utilizing a predictive marker in cancer therapy including better patient management minimizing unnecessary suffering from side effects with ultimately the wrong treatment choice, reducing loss of precious time whilst determining whether a therapy will provide any benefit, and a reduction in cost to both the patient and the wider health community. References reflist Category Cancer treatments ... more details
Multiple issues orphan March 2012 unreferenced March 2010 Curaxys is a biopharmaceutical company specializing in the research, development and production of biosimilar generic biological drugs. The company is located in the Technological Park of Puerto de Santa Maria, in Cadiz , Spain . Curaxys has been the pioneer citation needed date December 2011 in the use of insect cells in the production of biosimilar drugs. Previously, the insect cell culture platform was used solely for vaccine production, and never for other therapeutic proteins . citation needed date March 2012 Curaxys is also developing new technological platforms based on such other expression system s as bacteria , virus es and yeast . The company is developing the recombinant proteins Insulin , Growth Hormone , Erythropoietin , and Granulocyte colony stimulating factor GCSF it is also developing the Monoclonal antibody monoclonal antibodies Rituximab and Trastuzumab . Other therapeutic proteins are under development, including non monoclonal antibodies . Category Pharmaceutical companies of Spain ... more details
used in the pivotal phase III CLEOPATRA Clinical Evaluation of Pertuzumab and Trastuzumab trial was as follows ...&type abstract Link text ref The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first line treatment for HER2 positive ... test Baselga J, Cort s J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus ... more details
Drugbox Verifiedfields changed verifiedrevid 457120720 Monoclonal antibody data type mab mab type 3funct source axo target HER2 neu , CD3 receptor CD3 Clinical data tradename pregnancy AU pregnancy US pregnancy category legal AU legal CA legal UK legal US legal status routes of administration Pharmacokinetic data bioavailability protein bound metabolism elimination half life excretion Identifiers CAS number Ref cascite changed ?? CAS number 509077 99 0 ATC prefix none ATC suffix PubChem DrugBank Ref drugbankcite correct drugbank DrugBank ChemSpiderID Ref chemspidercite correct chemspider ChemSpiderID NA Chemical data chemical formula molecular weight Ertumaxomab trade name Rexomun is a rat mouse murine hybrid monoclonal antibody designed to treat some types of cancer . Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius company Fresenius development plans. ref http www.clinicaltrials.gov ct2 show NCT00522457 ClinicalTrials.gov Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy ref It is a so called trifunctional antibody which works by linking T lymphocyte s and macrophage s to the cancer cell s. ref http www.fresenius.se internet fag com faginpub.nsf Content P Info2004 01 15 Fresenius ref References reflist Monoclonals for tumors Category Monoclonal antibodies for tumors monoclonal antibody stub antineoplastic drug stub it Ertumaxomab ... more details
Deleted image removed File AU565 synonomous with SkBr3 Cells 20x Magnification.jpg thumb right AU565 Cells 20x Magnification Synonymous with SkBr3 Cells SkBr3 is a cell line isolated by the Memorial Sloan Kettering Cancer Center in 1970. It was derived from a pleural effusion due to an adenocarcinoma originating in the breast of a 43 year old, caucasian female. The cell line over expresses the HER2 gene product. ref name cite1 cite web title AATC Product Description url http www.lgcstandards atcc.org LGCAdvancedCatalogueSearch ProductDescription tabid 1068 Default.aspx?ATCCNum HTB 30&Template cellBiology accessdate 26 February 2012 ref The SkBr3 line is synonymous derived from the same patient with the AU565 cell line. ref cite web title LBL Breast Cancer Cell Collection Cell Line AU565 url http cancer.lbl.gov breastcancer viewline.php?id 4 accessdate 26 February 2012 ref The SkBr3 cell line has been used in studies seeking to overcome Herceptin resistance to HER2 overexpressing breast cancer. ref cite web title Overcoming Trastuzumab Resistance in HER2 Overexpressing Breast Cancer Cells by Using a Novel Celecoxib Derived Phosphoinositide Dependent Kinase 1 Inhibitor url http molpharm.aspetjournals.org content 70 5 1534.full accessdate 26 February 2012 ref The cells are considered biosafety level 1. ref name cite1 References Reflist Category Cell lines ... more details
3 pages 353 9 doi 10.1016 j.ygyno.2005.06.012 ref Trastuzumab In a recent study, about 60 of USCs ... s. The monoclonal antibody trastuzumab Herceptin is currently being tested as a therapy for this subset ... S. title Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma ... 18555254 doi 10.1016 j.ijgo.2008.04.008 ref The antibody trastuzumab Herceptin , which is used to treat ... more details
Trastuzumab emtansine T DM1 , an anti HER2 neu antibody drug conjugate ref National Cancer Institute http www.cancer.gov drugdictionary ?CdrID 564399 trastuzumab MCC DM1 antibody drug conjugate ref ref http www.immunogen.com wt page trastuzumab DM1 Immunogen Trastuzumab DM1 ref File Emtansine ... more details
biomarkers are as follows Trastuzumab HER 2 neu, ref name r4 ref name r5 ref name r6 Antiestrogens ... estrogen drugs and Trastuzumab than standard methods. In addition DirectHit displayed exceptional predictive ... value of HER2 in breast cancer. Oncology. 2001 61 73 82 ref ref name r5 Emens LA Trastuzumab ... with efficacy of trastuzumab therapy. Oncology 2002 16 1340 1355 ref ref name r7 Swain SM ... to Trastuzumab Therapy in Metastatic Breast Cancer. Archives of Pathology and Laboratory Medicine ... more details
is a mechanism of Trastuzumab resistance in HER2 breast cancer patients. Thus, co treatment of trastuzumab with CDK2 inhibitors may be a valid strategy. ref Scaltriti M, Eichhorn PJ, Cortes J, et al. Cyclin E amplification overexpression is a mechanism of trastuzumab resistance in HER2 breast ... more details
monoclonal antibodies , including trastuzumab and rituximab , against tumors. ref cite journal doi ... interfere with the ability to generate ADCC responses in vitro during trastuzumab treatment. References ... more details
trastuzumab targeting HER2 neu , cetuximab and panitumumab both targeting the EGF receptor , using the BiTE approach. ref cite journal title Conversion of cetuximab, panitumumab, trastuzumab and omalizumab ... more details
Biological response modifiers , also known as BRM s, are substances that the human body produces naturally, as well as something that scientists can create in a lab. These substances arouse the body s response to an infection. Some of these are used to treat arthritis, cancer, and some other diseases. Biologics include Monoclonal antibodies, Interleukin 2, Interferon, various types of colony stimulating factors CSF, GM CSF, G CSF Immunotherapy makes use of BRMs to enhance the activity of the immune system to increase the body s natural defense mechanisms against cancer ref http www.cancerquest.org index.cfm?page 186 ref whereas BRMs for rheumatoid arthritis aim to reduce inflammation. Some of the effects of BRMs include nausea and vomiting, diarrhea , loss of appetite , fever and chills, muscle aches, weakness, skin rash, an increased tendency to bleed, or swelling. Citation needed date October 2008 Abciximab Mechanism of action A monoclonal antibody that binds to the glycoprotein receptor IIb IIIa on activated platelets, preventing aggregation. Clinical use Acute coronary syndrome s, percutaneous transluminal coronary angioplasty. Toxicity Bleeding, thrombocytopenia . Etanercept Enbrel Mechanism of action Recombinant form of human TNF receptor that binds Tumor necrosis factors TNF . Clinical use Rheumatoid arthritis , psoriasis , ankylosing spondylitis . Infliximab Remicade Mechanism of action A monoclonal antibody to Tumor necrosis factors TNF , proinflammatory cytokine. Clinical use Crohn s disease , rheumatoid arthritis , ankylosing spondylitis . Toxicity Respiratory infection , fever , hypotension . Predisposes to infections reactivation of latent TB . Rituximab Rituxan Mechanism of action A monoclonal antibody to CD20 surface immunoglobulin. Clinical use Lymphoma Trastuzumab Herceptin Mechanism of action A monoclonal antibody against HER2 neu erb B2 . Helps kill breast cancer cells that overexpress HER 2, possibly through antibody dependent cytotoxicity. Clini ... more details
List of drugs T Tr Tri tr tra trab tram trabectedin United States Adopted Name USAN trabedersen United States Adopted Name USAN traboxopine International Nonproprietary Name INN tracazolate International Nonproprietary Name INN Tracleer Tracrium tradecamide International Nonproprietary Name INN trafermin International Nonproprietary Name INN Tral tralokinumab International Nonproprietary Name INN tralonide International Nonproprietary Name INN tramadol International Nonproprietary Name INN tramazoline International Nonproprietary Name INN trametinib United States Adopted Name USAN , International Nonproprietary Name INN tramiprosate United States Adopted Name USAN tran trav Trancopal Trandate trandolapril International Nonproprietary Name INN trandolaprilat International Nonproprietary Name INN tranexamic acid International Nonproprietary Name INN tranilast International Nonproprietary Name INN Tranmep Trans Ver Sal transcainide International Nonproprietary Name INN Transderm scop Transderm Nitro transferrin aldifitox United States Adopted Name USAN trantelinium bromide International Nonproprietary Name INN Tranxene tranylcypromine International Nonproprietary Name INN trapencaine International Nonproprietary Name INN trapidil International Nonproprietary Name INN Trasicor trastuzumab emtansine International Nonproprietary Name INN trastuzumab International Nonproprietary Name INN Trasylol Travamulsion Travase Travasol Travatan Travert travoprost Internation Nonproprietary Name INN trax traz traxanox International Nonproprietary Name INN trazitiline International Nonproprietary Name INN trazium esilate International Nonproprietary Name INN trazodone International Nonproprietary Name INN trazolopride International Nonproprietary Name INN tre treb tres trebananib United States Adopted Name USAN trebenzomine International Nonproprietary Name INN trecadrine International Nonproprietary Name INN Trecator Sc trecovirsen International Nonproprietary Name INN trefentanil In ... more details
include ref name pmid19887469 cite journal author Roy V, Perez EA title Beyond trastuzumab small molecule ... JK, Pecorelli S. title Trastuzumab treatment in patients with advanced or recurrent endometrial ... antibody trastuzumab marketed as Herceptin . Trastuzumab is effective only in cancers where HER2 is over expressed. An important downstream effect of trastuzumab binding to HER2 is an increase .... ref name pmid17687157 cite journal author Telli ML, Hunt SA, Carlson RW, Guardino AE title Trastuzumab ... WJ, Lotz JP, Luftner D, Pichon MF, Lipton A title Serum HER 2 neu and relative resistance to trastuzumab ... of trastuzumab in metastatic breast cancer journal J. Clin. Oncol. volume 27 issue 10 pages 1685 93 ... more details
Infobox non profit name The Breast Cancer Research Foundation image type founded date 1993 tax id registration id founder Evelyn H. Lauder location New York, NY coordinates origins key people Myra J. Biblowit, President area served product mission focus Breast Cancer Research method revenue endowment num volunteers num employees num members subsid opponents owner non profit slogan Prevention and A Cure in our Lifetime former name homepage http www.bcrfcure.org www.bcrfcure.org dissolved footnotes The Breast Cancer Research Foundation BCRF is an independent, not for profit organization which has raised USD 350 million to support clinical and translational research at medical institutions worldwide. BCRF currently funds 186 scientists across the United States, Canada, Latin America, Europe, the Middle East, Australia, and Asia. ref cite web url http www.bcrfcure.org action grantees.html title BCRF Grantees publisher The Breast Cancer Research Foundation ref The BCRF s director of research is Larry Norton , MD, of Memorial Sloan Kettering Cancer Center . BCRF has funded basic research on genetic susceptibility to breast cancer, breast cancer stem cells, trastuzumab Herceptin , anti angiogenesis treatment with bevacizumab Avastin , MRI imaging, aromatase inhibitors , tamoxifen and also clinical trials of new treatments with the Translational Breast Cancer Research Consortium . ref http www.bcrfcure.org about impact.html our impact The Breast Cancer Research Foundation What We ve Accomplished ref BCRF was founded in 1993 by Evelyn Lauder , Senior Corporate Vice President of The Estee Lauder Companies . Lauder s first foray into breast cancer awareness was through an initiative by herself and Alexandra Penney , former editor of Self magazine SELF magazine , to make the pink ribbon an international symbol of breast cancer awareness. ref cite web url http www.bcacampaign.com us about look.shtml title Breast Cancer Awareness Campaign publisher The Est e Lauder Companies Inc ... more details
Cleanup date April 2008 H. Michael Shepard is an American cancer researcher. He holds a bachelor s degree from the University of California, Davis . He received a Ph.D. from the Indiana University . Dr. Shepard was a Damon Runyon Cancer Research Foundation Fellow at Indiana University. He, is a founder, president and CSO of Receptor BioLogix, a California based biopharmaceutical company focused on developing a newly discovered class of protein therapeutics called Intron Fusion Proteins IFP to treat cancer, autoimmune, metabolic and other diseases. Formerly, he was chief scientific officer and vice president of research at Canji, Inc., where he developed the application of the p53 gene product for cancer treatment. While at Genentech, he led the discovery and development of the breast cancer drug, Trastuzumab trade name Herceptin . Dr. Shepard shared the 2006 Alpert Prize for his contribution to the development of the breast cancer therapy Herceptin, the first target directed cancer treatment for solid tumors. Dr. Shepard holds over 25 US patents. Patents US patent 7,138,388 &mdash Methods to treat autoimmune and inflammatory conditions US patent 7,105,156 &mdash Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells US patent 6,946,259 &mdash Compositions and methods for treating cells having double minute DNA US patent 6,683,061 &mdash Enzyme catalyzed therapeutic activation US patent 6,551,585 &mdash Use of tumor necrosis factor as an adjuvant US patent 6,495,553 &mdash Methods and compositions for overcoming resistance to biologic and chemotherapy US patent 6,399,063 &mdash Monoclonal antibodies directed to the HER2 receptor US patent 6,387,371 &mdash Monoclonal antibodies directed to the HER2 receptor US patent 6,348,352 &mdash Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene US patent 6,339,151 &mdash Enzyme catalyzed therapeutic agents US patent 6,333,169 &mdash HER2 ... more details
notability date March 2009 Ann Marie Rogers was a United Kingdom British campaigner who fought a successful landmark court battle to receive the breast cancer drug Herceptin on the NHS. ref http www.lastingtribute.co.uk tribute rogers 3035640 Tribute site to Rogers ref ref Irwin Mitchell http www.irwinmitchell.com news Pages herceptin woman loses fight for life.aspx ref Following her diagnosis with the disease and chemotherapy and radiotherapy, Swindon Primary Care Trust refused to pay for the Herceptin which could extend her life. ref www.careandhealthlaw.com http www.careandhealthlaw.com Public Index.aspx?ContentID 66&IndexType 1&TopicID 467&Category 1 ref She borrowed 5,000 to pay for the drug, hailed by specialists as the biggest breakthrough in 20 years ref Ann Marie Rogers, Daily Mail http www.dailymail.co.uk health article 387615 Herceptin So wonder drug.html ref privately and decided to go further after reading in the Daily Mail about the possibility of legal action. She was the first woman to pursue a legal challenge when Swindon primary care trust denied her the drug. Rogers originally lost her High Court of Justice High Court case, but took it to the Court of Appeal in April 2006 who overturned the original ruling. ref http www.dailymail.co.uk news article 1159703 Brave mother won NHS battle drug denied breast cancer sufferers dies aged 57.html Court of Appeal ruling ref Yogi Amin, from law firm Irwin Mitchell, who represented Ms Rogers throughout her legal battle, said that her courage had paved the way for thousands of women throughout the UK to benefit from Herceptin. ref The Times http www.timesonline.co.uk tol news uk health article5853302.ece ref The drug was fast tracked for use on the NHS as a result. ref BBC News http news.bbc.co.uk 1 hi health 5058952.stm ref Herceptin trastuzumab is a treatment for women with breast cancer whose tumors have too much HER2 protein. This type of cancer is known as HER2 positive , HER2 , or HER2 overexpressing . HE ... more details
chemotherapeutic agents, such as anthracycline , taxane derived drugs, or trastuzumab Herceptin ... treated with those agents anthracycline, a taxane and trastuzumab demonstrated that administrating ... and trastuzumab. Adverse effects Like many small molecule tyrosine kinase inhibitors, lapatinib ... more details
2 is often overexpressed in breast cancer. The drug Trastuzumab Herceptin targets this receptor. Only one third of the women respond to Trastuzumab, and recently it was not known what causes the resistance to Trastuzumab. It is revealed that patients with ER HER2 compared with ER HER2 breast cancers ... more details
Encyclopedia
top
